These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9379696)

  • 1. Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer.
    Wehbe TW; Stein BS; Akerley WL
    Mayo Clin Proc; 1997 Oct; 72(10):932-4. PubMed ID: 9379696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate.
    Burch PA; Loprinzi CL
    J Clin Oncol; 1999 Mar; 17(3):1087-8. PubMed ID: 10071307
    [No Abstract]   [Full Text] [Related]  

  • 3. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome.
    Dawson NA; McLeod DG
    J Urol; 1995 Jun; 153(6):1946-7. PubMed ID: 7538601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.
    Dawson NA; Conaway M; Halabi S; Winer EP; Small EJ; Lake D; Vogelzang NJ
    Cancer; 2000 Feb; 88(4):825-34. PubMed ID: 10679652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antiandrogen withdrawal syndrome].
    Akimoto S
    Nihon Rinsho; 1998 Aug; 56(8):2135-9. PubMed ID: 9750522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of megestrol acetate as monotherapy in disseminated prostatic carcinoma].
    Gallo Rolania FJ
    Arch Esp Urol; 1998 Mar; 51(2):151-3. PubMed ID: 9586312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megestrol acetate in the treatment of hormone refractory prostate cancer.
    Osborn JL; Smith DC; Trump DL
    Am J Clin Oncol; 1997 Jun; 20(3):308-10. PubMed ID: 9167760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Herrada J; Dieringer P; Logothetis CJ
    J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
    Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate.
    Vollmer RT; Dawson NA; Vogelzang NJ
    Cancer; 1998 Nov; 83(9):1989-94. PubMed ID: 9806658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of prostate-specific antigen expression by synthetic progestins in patients with prostate and breast cancer.
    Diamandis EP
    Mayo Clin Proc; 1998 Jul; 73(7):706-7. PubMed ID: 9663206
    [No Abstract]   [Full Text] [Related]  

  • 14. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
    Heng DY; Chi KN
    Can J Urol; 2006 Dec; 13(6):3335-9. PubMed ID: 17187697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer: good response with tolerability.
    Azuma H; Inamoto T; Takahara K; Ibuki N; Koyama K; Utimoto S; Fujisue Y; Uehara H; Komura K; Nomi H; Ubai T; Katsuoka Y
    Anticancer Res; 2010 Sep; 30(9):3737-45. PubMed ID: 20944163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
    Semeniuk RC; Venner PM; North S
    Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
    Kobayashi M; Kuramoto H; Ota J; Fujimoto N
    Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.